Recruiting

NCT Number: NCT04191395

Evolution and Treatments of Chronic Inflammatory Systemic Diseases

Patients with chronic inflammatory diseases (CID) followed in gastroenterology, dermatology and rheumatology have physiopathological, epidemiological and therapeutic focal points. The pathologies concerned are inflammatory bowel diseases (IBD - Crohn's disease [MC] and ulcerative colitis [RCH]), chronic inflammatory skin diseases (psoriasis or Verneuil's disease) and chronic inflammatory rheumatic diseases (rheumatoid arthritis [RA] and spondyloarthritis [SpA] including psoriatic arthritis [PsA]). Presenting one of these diseases is associated with a higher risk of having a second inflammatory pathology, whether the latter is ophthalmological, dermatological, rheumatological or gastroenterological. An association of extra-articular manifestations is observed in 10 to 30% of patients with SpA, and an association of extra-intestinal manifestations is observed in approximately 30% of patients with IBD. No common database for chronic systemic inflammatory diseases currently exists in France.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Inflammatory Bowel Diseases Arthritis Arthritis, Psoriatic Arthritis, Rheumatoid Autoimmune Diseases Bacterial Infections Bacterial Infections and Mycoses Bone Diseases Colitis Colitis, Ulcerative Colonic Diseases Connective Tissue Diseases Crohn Disease Digestive System Diseases Gastroenteritis Gastrointestinal Diseases Hidradenitis Hidradenitis Suppurativa Immune System Diseases Infections Intestinal Diseases Joint Diseases Musculoskeletal Diseases Psoriasis Psoriatic Arthritis Rheumatic Diseases Skin Diseases Skin Diseases, Bacterial Skin Diseases, Infectious Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases Spinal Diseases Spondylarthritis Spondylarthropathies Spondylitis Spondyloarthritis Suppuration Sweat Gland Diseases Ulcerative Colitis Verneuil's Disease

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Besançon

Besançon, 25000, France

Location status: Recruiting

Location contact

Charline Vauchy, PhD

CONTACT

[email protected]

Clément Prati, Prof.

CONTACT

François Aubin, Prof.

CONTACT

Lucine Vuitton, Prof.

CONTACT

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients treated for IBD (MC, UC or indeterminate colitis) in the gastroenterology department of Besançon University Hospital
Subject meeting the clinical, morphological and histological diagnostic criteria for MC, UC or indeterminate colitis or
Patients treated for chronic inflammatory rheumatism (RA, SpA, PsA) in the rheumatology department of the University Hospital of Besançon Subject meeting the ACR 2010 classification criteria of RA or modified New York criteria of Ankylosing spondylitis or ASAS criteria of axial or peripheral SpA or CASPAR criteria of PsA or
Patients treated for chronic inflammatory skin disease (Psoriasis, Verneuil's disease) in the dermatology department of the University Hospital of Besançon

Exclusion criteria

Opposition of the patient
Patients in emergency situation, persons deprived of their liberty, protected minors or adults.

Treatment and study plan

Primary outcomes

Diagnosis of a second inflammatory disease

Time frame: through study completion (up to 10 years)

Study contacts

Contact information is provided by the study sponsor or research team.

Charline Vauchy, PhD

CONTACT

[email protected]

0381218875

Stéphanie François

CONTACT

sfrancois@chu-besançon.fr

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Besancon

Other

Registry information

Official study title

Evolution and Treatments of Chronic Inflammatory Systemic Diseases: Implementation of a Hospital Cohort in the Gastroenterology, Dermatology and Rheumatology Departments of the University Hospital of Besançon

Acronym: MISTIC

Important dates

Study start: 2019
Primary completion: 2029
Study completion: 2029
First posted: Dec 9, 2019
Registry last updated: Nov 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed